Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.
Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...
Industry-leading non-human primate (NHP) data validates CREATE's differentiated receptor design, targeted RNA-LNP platform, and ability to repeat dose Clinical entry planned H2 2026 CAMBRIDGE, Mass., ...
Epstein-Barr virus (EBV) infected and reprogrammed autoreactive B cells in patients with systemic lupus erythematosus (SLE) to become activated antigen-presenting cells. EBV-infected B cells in ...
A new artificial intelligence (AI) tool can simultaneously assess blood samples for infections, autoimmune diseases, and vaccine responses, according to a new study. The algorithm analyzed genes ...
Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's positive outcomes. The FELIX trial reported a 63% complete remission rate, with 42 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results